Cingulate Inc. Form 8-K Summary
Business Context and Reporting Period
Cingulate Inc. (CING), an emerging growth company incorporated in Delaware, filed this Current Report on Form 8-K on July 21, 2025. The report details unregistered sales of equity securities occurring between March 31, 2025, and July 21, 2025. The company's common stock and warrants trade on the Nasdaq Capital Market.
Key Financial Metrics and Transactions
This filing does not provide comprehensive financial statements, revenue, profit, or cash flow data. It specifically reports the issuance of unregistered equity securities as follows:
- May 12, 2025: Issued 7,538 shares of Common Stock to a service provider at $4.36 per share.
- July 8, 2025: Granted an option award to an officer for 30,000 shares at an exercise price of $4.51 per share. The award vests over four years (25% after one year, remainder monthly).
- July 10, 2025: Issued 5,986 shares of Common Stock to a lender at $4.18 per share in exchange for debt.
- July 14, 2025: Issued 57,471 shares of Common Stock to a lender at $4.35 per share in exchange for debt.
- July 21, 2025: Issued 73,068 shares of Common Stock to a lender at $4.79 per share in exchange for debt.
Total shares issued for debt repayment in July 2025: 136,525 shares.
Material Changes
The filing discloses a material change in the company's capital structure through the issuance of approximately 174,063 shares of common stock and one option grant during the reporting period. A significant portion of these issuances (136,525 shares) was executed to settle outstanding debt obligations with lenders.
Outlook, Risks, and Management Commentary
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure of unregistered securities. The transactions were exempt from registration under Sections 4(a)(2) and 3(a)(9) of the Securities Act of 1933.
Investor Verification Checklist
- Verify the total outstanding debt remaining after the July debt-for-equity conversions.
- Confirm the dilution impact of the 174,063 newly issued shares on existing shareholders.
- Review the vesting schedule and potential future dilution from the 30,000-share officer option grant.
- Check subsequent filings for any additional unregistered issuances or changes in the company's liquidity position.